Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...
Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...
Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...
U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and ...
Eli Lilly and Co. announced this morning that it will boost its investment in Lebanon to more than $13 billion. The move increases Lilly's capital commitment in the United States to more than $23 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback